Tolerability and adherence issues in antidepressant therapy (Q35544757)

8 August 2017

1 reference

title

Tolerability and adherence issues in antidepressant therapy (English)

1 reference

8 August 2017

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

14 March 2024

author name string

Prakash S. Masand

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512135

14 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14512135

14 March 2024

publication date

1 August 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0149291803802205?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

https://api.elsevier.com/content/article/PII:S0149291803802205?httpAccept=text/plain

14 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

14 March 2024

published in

Clinical Therapeutics

1 reference

8 August 2017

25

1 reference

8 August 2017

8

1 reference

8 August 2017

2289-2304

1 reference

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

The role of the primary care physician in patients' adherence to antidepressant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

What role do atypical antipsychotic drugs have in treatment-resistant depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

The compliance with antidepressants in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Discontinuing or switching selective serotonin-reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Discontinuation of use and switching of antidepressants: influence of patient-physician communication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Adequacy and duration of antidepressant treatment in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Suboptimal duration of antidepressant treatments in the older ambulatory population of Quebec: association with selected physician characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

National trends in the outpatient treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Changing patterns of antidepressant use and costs in a health maintenance organisation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Selecting methodologies for the evaluation of differences in time to response between antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Comorbid depression and anxiety spectrum disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Antidepressant-induced sexual dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Placebo response in studies of major depression: variable, substantial, and growing

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

'New' and 'old' antidepressants: all equal in the eyes of the lore?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Systematic review and guide to selection of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Combining antidepressants for treatment-resistant depression: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Are atypical antipsychotic drugs also atypical antidepressants?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980220-5

7 January 2021

Unmet need: what justifies the search for a new antidepressant?

1

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

Current perspectives on the diagnosis and treatment of major depressive disorder

14 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

Long-term treatment of depression

14 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

Prevalence and outcome of partial remission in depression

14 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline

14 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

Combining Antidepressants for Treatment-Resistant Depression

14 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80220-5

14 March 2024

Identifiers

1 reference

8 August 2017

1 reference